Judit Meszaros Jørgensen

5PUBLICATIONS
30CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 05, 2026
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

|Nov 27, 2023
Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas.

Ahmed Ludvigsen Al-Mashhadi, Lasse Hjort Jakobsen, Peter Brown

|Sep 02, 2022
Low lymphocyte-to-monocyte ratio predicts poor outcome in high-risk aggressive large B-cell lymphoma.

Heli Vajavaara, Suvi-Katri Leivonen, Judit Jørgensen

|Jun 09, 2022
Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy.

Joachim Baech, Marianne Tang Severinsen, Andreas K Øvlisen

|Dec 21, 2021
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.

Leo Meriranta, Amjad Alkodsi, Annika Pasanen

Pageof 1

Frequent Collaborators

3 joint publications

Peter Brown

2 joint publications

Harald Holte

2 joint publications

Sirpa Leppä

2 joint publications

Michael Roost Clausen